Mitochondrial DNA in Osteoarthritis Disease

UDC.coleccionInvestigaciónes_ES
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicases_ES
UDC.endPage3259es_ES
UDC.grupoInvGrupo de Investigación en Reumatoloxía e Saúde (GIR-S)es_ES
UDC.grupoInvReumatoloxía (INIBIC)es_ES
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruñaes_ES
UDC.journalTitleClinical Rheumatologyes_ES
UDC.startPage3255es_ES
UDC.volume39es_ES
dc.contributor.authorBlanco García, Francisco J
dc.contributor.authorRego-Pérez, I.
dc.date.accessioned2020-10-20T09:57:05Z
dc.date.embargoEndDate2021-09-25es_ES
dc.date.embargoLift2021-09-25
dc.date.issued2020-09-25
dc.description.abstract[Abstract] Osteoarthritis (OA) is the most prevalent chronic joint disease, and we actually know that the activation of maladaptive responses to injury, including pro-inflammatory pathways, leads to the loss of normal joint function characterized by cartilage degradation, bone remodeling, osteophyte formation, and joint inflammation [1]. Recent insights into the epidemiology and impact of OA on patients have clearly established that OA is a severe disease of the whole joint as an organ, with large unmet medical needs. OA has a complex etiology that comprises the combination of multiple factors, including gender, age, occupation, trauma, body mass index, and genetics. Approximately, between 30 and 65% of the risk of OA is genetically determined [2] with evidence accumulated from different genome-wide association studies (GWAS) [3]. Most of these studies focused on nuclear genetic variants; however, over the last decade, evidence has accumulated for an association between specific mitochondrial DNA (mtDNA) genetic variants, called haplogroups, and different OA-related features, including prevalence, progression, and incidence [4].es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CIBERCB06/01/0040es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; RETIC-RIER-RD16/0012/0002es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PRB2-ISCIII-PT17/0019/0014es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI14/01254es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI16/02124es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI17/00210es_ES
dc.identifier.citationBlanco FJ, Rego-Pérez I. Mitochondrial DNA in osteoarthritis disease. Clin Rheumatol. 2020; 39:3255–3259es_ES
dc.identifier.issn1434-9949
dc.identifier.issn0770-3198
dc.identifier.urihttp://hdl.handle.net/2183/26472
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.urihttps://doi.org/10.1007/s10067-020-05406-8es_ES
dc.rightsThe final publication is avaliable at Springer Linkes_ES
dc.rights.accessRightsopen accesses_ES
dc.titleMitochondrial DNA in Osteoarthritis Diseasees_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationf357279a-035a-4279-a553-99cfd79bd2bb
relation.isAuthorOfPublication.latestForDiscoveryf357279a-035a-4279-a553-99cfd79bd2bb

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Blanco_Francisco_2020_Mitochondrial_DNA_Osteoarthritis_Disease.pdf
Size:
151.13 KB
Format:
Adobe Portable Document Format
Description: